Couldn’t agree with you any more @nailsnglue. I guess we have to take the rough with the smooth when the share price falls south. (Regardless if it’s being manipulated by shorter) just as quick as the price retreats we have seen it move north just as fast. Its only going to take a positive announcement to rocket it back into 1.30.
Its not fun to watch the share price fall south but I’m reassured by the re reading announcements about the in vivo studies that RCE have completed. Call me naïve but I feel that investing in RCE at these prices and at this time, are low risk.
We know that R327 works on burn wounds in animal models, and we know that R327 cause “no evidence or discomfort” with a skin irritation test. Wound contraction is “better than market drug” and bacteria cant build up resistance to R327.
The special access scheme has demonstrated that R327 is safe to use, and works. We just need to validate it through clinical testing.
Fidelity invested $27,950,000 (I’m sure they did their due diligence in research before investing) at the time I wasn’t thrilled about it. but seeing we now have 20.87 million in the bank to fund phase 2/3 trials with sepsis it actually was a master stroke by James and the team to lock in a financial institution and a war-chest of funds.
Congratulations to anyone who toped up below 80c today
(20min delay)